|
Originally published In Press as doi:10.1074/jbc.M011564200 on April 4, 2001
J. Biol. Chem., Vol. 276, Issue 26, 23937-23944, June 29, 2001
Neurosteroid Hydroxylase CYP7B
VIVID REPORTER ACTIVITY IN DENTATE GYRUS OF GENE-TARGETED MICE
AND ABOLITION OF A WIDESPREAD PATHWAY OF STEROID AND OXYSTEROL
HYDROXYLATION*
Ken
Rose ,
Adrian
Allan§,
Stephan
Gauldie ,
Genevieve
Stapleton ,
Lorraine
Dobbie ,
Karin
Dott¶,
Cécile
Martin ,
Ling
Wang§,
Eva
Hedlund§,
Jonathan R.
Seckl **,
Jan-Åke
Gustafsson§**, and
Richard
Lathe 
From the Centre for Genome Research and Centre for
Neuroscience, University of Edinburgh, King's Buildings, Edinburgh EH9
3JQ, United Kingdom, the § Karolinska Institute,
14186 Huddinge, Sweden, ¶ Transgène SA, 11 Rue de
Molsheim, 67000 Strasbourg, France, and the Molecular Medicine
Centre, Western General Hospital, Crewe Road, Edinburgh EH4
2XU, United Kingdom
Received for publication, December 21, 2000, and in revised form, April 3, 2001
 |
ABSTRACT |
The major adrenal steroid
dehydroepiandrosterone (DHEA) enhances memory and immune function but
has no known dedicated receptor; local metabolism may govern its
activity. We described a cytochrome P450 expressed in brain and other
tissues, CYP7B, that catalyzes the 7 -hydroxylation of oxysterols and
3 -hydroxysteroids including DHEA. We report here that CYP7B mRNA
and 7 -hydroxylation activity are widespread in rat tissues. However,
steroids related to DHEA are reported to be modified at positions other
than 7 , exemplified by prominent 6 -hydroxylation of
5 -androstane-3 ,17 -diol (A/anediol) in some rodent tissues
including brain. To determine whether CYP7B is responsible for these
and other activities we disrupted the mouse Cyp7b gene by
targeted insertion of an IRES-lacZ reporter cassette,
placing reporter enzyme activity ( -galactosidase) under Cyp7b promoter control. In heterozygous mouse brain,
chromogenic detection of reporter activity was strikingly restricted to
the dentate gyrus. Staining did not exactly reproduce the in
situ hybridization expression pattern; post-transcriptional
control is inferred. Lower level staining was detected in cerebellum, liver, and kidney, and which largely paralleled mRNA distribution. Liver and kidney expression was sexually dimorphic. Mice homozygous for
the insertion are viable and superficially normal, but ex vivo metabolism of DHEA to 7 -hydroxy-DHEA was abolished in
brain, spleen, thymus, heart, lung, prostate, uterus, and mammary
gland; lower abundance metabolites were also eliminated.
7 -Hydroxylation of 25-hydroxycholesterol and related substrates was
also abolished, as was presumed 6 -hydroxylation of A/anediol. These
different enzyme activities therefore derive from the Cyp7b
gene. CYP7B is thus a major extrahepatic steroid and oxysterol
hydroxylase and provides the predominant route for local metabolism of
DHEA and related molecules in brain and other tissues.
 |
INTRODUCTION |
Brain function is subject to hormonal control, notably by steroids
synthesized from the adrenal glands and gonads. Accumulating evidence
also points to local steroid synthesis and metabolism in brain; a
growing field of investigation focuses on the biological role of
brain-active steroids, or "neurosteroids" (1-5). Attention has
focused on the major adrenal steroid in primates,
dehydroepiandrosterone (DHEA),1 in view of a
possible link with cognitive aging and immunosenescence. DHEA and
related steroids, including pregnenolone, have memory-enhancing properties in rodents (6-8) as well as immunostimulatory effects (9-11). In primates, levels of DHEA and its sulfate (DHEAS) decline asymptotically with age (12-14). A causal relationship with
age-related physiological impairments has been debated (15, 16).
Because DHEA replacement therapy has brought mixed results (15,
17-19), and no dedicated receptor has been described for DHEA, its
bioactivity may require local metabolism.
B-ring hydroxylation is a major metabolic route for
3 -hydroxysteroids, including DHEA and pregnenolone, in diverse
tissues including brain, heart, liver, mammary and adipose tissue,
ovary, pituitary, prostate, spleen, and thymus (20-32). In rodent
brain, 7 -hydroxylation is the major ex vivo metabolic
route for DHEA, pregnenolone, and A/enediol (24, 25, 29, 31, 33-35)
and, in brain and other tissues, for oxysterols/bile acids (25- and 27-hydroxycholesterol, 3 -hydroxy-5-cholestenoic acid,
3 -hydroxy-5-cholenoic acid; Ref. 29), although 7 - and
6 -hydroxylation have also been recorded. Nevertheless, the
identities of the enzymes responsible for these diverse activities have
not been fully elucidated.
We reported the molecular cloning, from rat and mouse hippocampus, of a
new cytochrome P450 with steroid-modifying potential (36). The enzyme
is most homologous (39%) to hepatic cholesterol 7 -hydroxylase,
CYP7A (37), and more distantly related to CYP8A (prostacyclin synthase;
Ref. 38) and CYP8B (sterol 12 -hydroxylase; Ref. 39). Expressed from
recombinant vaccinia virus, the mouse enzyme metabolized DHEA to
7 -hydroxy-DHEA (7HD) (Ref. 40); pregnenolone, estradiol (E2), and
oxysterols, including 25-hydroxycholesterol, are also converted by the
recombinant enzyme (40, 41) (Fig. 1A). However, the exact
relationship of CYP7B enzyme to the observed ex vivo
steroid hydroxylation activities is not known.
Multiple enzymes may be present. First, CYP7B emerged from a screen for
hippocampus-specific genes (36); steroid hydroxylation in different
brain regions may be mediated by other enzyme(s). Second, inhibitor
studies argue that separate enzymes catalyze the 7 - and
7 -hydroxylation of DHEA and pregnenolone in brain (31, 33-35).
Third, metabolism of A/anediol in rodent brain and also prostate is
principally at the 6 position (24-26, 28), perhaps indicative of a
separate A/anediol hydroxylase enzyme.
To address these questions the identity of the brain enzyme, its
relationship to the observed activities, and expression pattern, we
prepared mice harboring a targeted insertion of a reporter gene
cassette (IRES-lacZ) into Cyp7b. We describe
reporter gene activity in brain and other tissues and explore
alterations in ex vivo steroid hydroxylation in tissues of
Cyp7b / mice. We argue that the Cyp7b locus
encodes a major pathway of extrahepatic steroid and oxysterol hydroxylation.
 |
EXPERIMENTAL PROCEDURES |
Steroid Conversions and Northern Blotting--
Tissue extracts,
recombinant vaccinia-expressing CYP7B, and assays for hydroxylation
activity were as described previously (40). Substrates
[14C-]DHEA, [3H]25-hydroxycholesterol,
[3H]A/enediol, [3H]A/anediol,
[3H]5 -androstane-3 ,17 -diol; (45-60 mCi/mmol for
14C; 20-95 Ci/mmol for 3H) were purchased from
PerkinElmer Life Sciences. Tissue homogenates (50 µl) in
Waxman's buffer (0.1 M KPO4, 1 mM
EDTA, 20% w/v glycerol, pH 7.5) were incubated (200 µl volume
containing 1 mM NADPH) with radiolabeled substrates for 20 min at 37 °C; steroids were extracted with ethyl acetate, dried,
taken up in ethyl acetate, applied to aluminum-backed silica gel TLC
plates (Merck), and developed using the buffer system N of Waxman
(ethyl acetate/n-hexane/acetic acid, 16:8:1). Chromatograms
were visualized by autoradiography. Northern blotting was according to
conventional techniques using nylon (Hybond N, Amersham Pharmacia
Biotech); hybridization used riboprobes at 68 °C under
conditions as described previously (42).
Gene Targeting in ES Cells--
A segment of mouse DNA
encompassing exons I-IV of the Cyp7b gene was isolated from
a library of 120/Ola genomic DNA in 2001 by probing with a
subgenomic clone previously isolated (65). The exon-intron
structure is similar to that described for the gene encoding the
related enzyme, cholesterol 7 hydroxylase (43, 44).2 An
insertion/replacement construct was built in which the
IRES-lacZ cassette is stationed within Cyp7b exon
II. An 8-kb BamHI- HindIII fragment was
subcloned into pBluescriptII; and a 5-kb reporter/selection cassette,
comprising the LacZ enzyme coding sequence (lacking an artificial
nuclear localization signal) prefixed by a viral IRES element,
and also containing a neomycin phosphotransferase gene under
independent promoter control (MC1neo) and a polyadenylation sequence (45), was introduced at an internal BamHI site
within exon II (see Fig. 2). The hybrid construct was suffixed by two copies of a herpes simplex virus thymidine kinase expression cassette and transfected into E14-TG2a ES cells. Positive-negative selection (46) was used to enrich for targeted clones. Colonies were screened by
restriction enzyme digestion (PstI, EcoRI,
EcoRI + SalI) and Southern hybridization to
separate probes out with the homology arms (see Fig. 1). External
probes were: 150-nt HindIII-NarI fragment from the 5' end of
the mouse cDNA (clone 35 in Ref. 36) corresponding to exon I (5'
probe) and the 480 HindIII-BglII fragment from
clone 25 corresponding to exon III (3' probe).
Generation of Transgenic Mice--
Targeted ES cell clones were
injected into the blastocysts of strain C57BL/6 mice; chimeric males
were mated to strain C57BL/6 females. Progeny typing was by Southern
analysis of tail-tip DNA using the probes described above. Mice
were systematically backcrossed against C57BL/6 animals; the
experiments reported use animals of >3 backcross generations. To
prepare homozygotes, littermates were intercrossed for each experiment.
Reporter Gene Expression and in Situ Hybridization--
Frozen
tissue sections (10 µM) were transferred to TESPA
(2-aminoproplytriethoxyslilane)-coated slides, fixed (0.25% w/v
glutaraldehyde in 5 mM EGTA, 2 mM
MgCl2, 100 mM NaPO4, pH 7.3, 5 min), rinsed (2 mM MgCl2, 0.01% sodium
deoxycholate, 0.01% Nonidet-P40, 100 mM NaPO4,
pH 7.3), and stained (rinse buffer containing 1 mg/ml 5-bromo-4-chloro-3-indolyl -D-galactopyranoside
(X-gal), Life Technologies, Inc., 5 mM
potassium ferricyanide, 5 mM potassium ferrocyanide) at 37 °C for 4-16 h. For in situ
hybridization, TESPA slide-mounted tissue sections were fixed (4% w/v
paraformaldehyde, 15 min, 4 °C), deproteinized (20 µg/ml
proteinase K, 1 min; blocking with 0.2% glycine, 5 min), acetylated
(0.25% acetic anhydride, 0.1 M triethanolamine, pH 8, 0.8% w/v NaCl, 10 min), and dehydrated by passing via successively
increasing ethanol solutions (50-100% ethanol), immersed in
CHCl3, rinsed in ethanol, and air-dried. For hybridization,
sections were incubated overnight at 55 °C with
32P-labeled riboprobes (prepared by in
vitro transcription from pBluescript and pretreated with 10 mM dithiothreitol) in buffer containing 50% v/v deionized
formamide, 0.3 M NaCl, 20 mM Tris·Cl, pH 8, 5 mM EDTA, 10 mM NaPO4, pH 8, 10%
w/v dextran sulfate, 1 × Denhardt's solution, 0.5 mg/ml yeast
RNA). Higher stringency washing (2 × SSC, 0.1 M
dithiothreitol, 65 °C, 30 min) was followed by RNase treatment
(RNase A, 20 µg/ml, 30 min, 37 °C), washing, and dehydration
through increasing ethanol concentrations. Slides were exposed for
autoradiography (Kodak Biomax).
Immunohistochemistry--
Peptides CHEDLEIGAHHLGF and
CFEA- PEEFRYDRFIEDGKKKTT, designed from the sequences of rat, mouse,
and human CYP7B3 and prefixed
with N-terminal cysteines, were prepared by chemical synthesis
(Albachem Ltd., Edinburgh, United Kingdom) and conjugated with keyhole
limpet hemocyanin; we gratefully acknowledge Dr. N. Robertson's
assistance. Adjuvant-complexed peptides were pooled before inoculation
into sheep (Scottish Antibody Production Unit, Carluke, Scotland),
generating sera S897 and S898. Immunohistochemistry was performed on
perfused and paraformaldehyde-fixed brain sections and developed
using a biotinylated second antibody, peroxidase-avidin complex, and
diaminobenzidine tetrahydrochloride.
 |
RESULTS |
Widespread Expression of Steroid Hydroxylase Activity and CYP7B
mRNA in Rat Tissues--
We assessed the tissue distribution of
steroid hydroxylation activity, measured biochemically, and of CYP7B
mRNA, measured by Northern blotting. Fig.
1B confirms CYP7B mRNA in
many rat tissues including brain, spleen, heart, prostate, lung, and
ovary, in addition to kidney and liver as reported previously
(36). Biochemical analysis of different rat tissues revealed that most if not all tissues can convert DHEA to more polar metabolites. Prominent hydroxylation of DHEA to a product comigrating with 7 -hydroxy-DHEA (7HD) took place in brain extracts, as reported previously (40), and was also demonstrated in spleen, heart, prostate,
seminal vesicles, and uterus (Fig. 1C) as well as in lung,
uterus, and mammary gland (not presented). Some other tissues gave some
indication of products comigrating with 7HD (lung, testis, kidney,
liver), but many metabolites failed to comigrate with 7HD, suggesting
that other pathways also operate. A similar broad distribution of
hydroxylation activity was also observed with A/anediol, A/enediol, and
25-hydroxycholesterol, while the 3 -hydroxylated substrate
5 -androstane-3 ,17 -diol was not significantly metabolized in
most tissues including brain (data not presented). We conclude that
CYP7B enzyme and 7 -hydroxylation activities are widely expressed in
rat tissues.

View larger version (77K):
[in this window]
[in a new window]
|
Fig. 1.
Steroid hydroxylation and CYP7B mRNA in
rat tissues. A, reaction catalyzed by CYP7B enzyme.
B, Northern analysis of rat tissues probed with CYP7B or
ribosomal protein S26 (internal control). C, ex
vivo DHEA hydroxylation in rat tissues analyzed by ascending TLC.
Tissues (B and C) were: brain (Br),
spleen (Sp), heart (He), prostate
(Pr), seminal vesicle (Se), uterus
(Ut), testis (Te), lung (Lu), ovary
(Ov), kidney (Ki), liver (Li)
(extracts of male (m) and female (f) animals);
DHEA, substrate only. m1, molecule 1 (see text).
Filled arrowheads, DHEA substrate; open
arrowheads, sample application.
|
|
Targeting the Mouse Cyp7b Gene--
To address the relationship
between CYP7B expression and steroid/sterol hydroxylation, we disrupted
the mouse Cyp7b gene. To track CYP7B expression, a bacterial
reporter gene (lacZ) was inserted into exon II downstream of
the Cyp7b promoter and prefixed with a viral IRES
element permitting efficient translation from the lacZ
cistron (Fig. 2A). Homologous
recombination in ES cells introduced the IRES-reporter
segment into the resident gene. Clones were screened by Southern
blotting using internal and external probes; a large proportion gave
the expected pattern (Fig. 2B). Male chimeras were generated
by blastocyst injection, crossed to C57BL/6 females; heterozygous
transgenic progeny of these chimeras appeared at the expected Mendelian
ratio (not presented). Further work employed the progeny of one
representative targeted line.

View larger version (29K):
[in this window]
[in a new window]
|
Fig. 2.
Gene targeting of the mouse Cyp7b
locus. A, exons I-IV of the Cyp7b
gene, showing insertion of the IRES-lacZ-pMC1-neo cassette
into exon II; restriction sites are PstI (P),
BamHI (B), HindIII (H),
EcoRI (E), SalI (S),
XhoI (X), BglII/BamHI
fusion site (Bg/B). HSV TK is the thymidine kinase gene of
herpes simplex virus. B, Southern analysis of targeted
clones; restriction sites and digests are the same as explained in
A.
|
|
Reporter Activity in Liver and Kidney--
The targeted locus
harbors an insertion of the bacterial -galactosidase reporter, LacZ,
under independent translational control; enzyme activity was
anticipated to reiterate the pattern and level of transcription of the
endogenous Cyp7b gene. Liver and kidney sections were
stained with a chromogenic substrate for LacZ. No staining was seen in
nontransgenic tissues (Fig.
3A, panel a, and
B, panel a); marked staining was detected in both
liver and kidney of transgenic animals and was sexually dimorphic. In
male liver, neonatal expression of CYP7B-LacZ was limited to discrete foci (Fig. 3A, panel b); in the adult staining
was associated primarily with hepatocytes rather than Kupfer cells or
other elements and was mostly in the perivenous zone of the hepatic
lobules (Fig. 3A, panels c and
d). No significant staining was seen in adult female liver
(Fig. 3A, panels e and f). In
male kidney, reporter staining was maximal in the outer stripe of the
medulla (Fig. 3B, panel b). Within the outer
stripe, staining was most intense in cells with more abundant cytoplasm
in the S3 segment of the proximal tubule (Fig. 3B,
panels c and d). In female kidney, as in liver,
staining was poor to indetectable (Fig. 3B,
panels e and f).

View larger version (68K):
[in this window]
[in a new window]
|
Fig. 3.
Expression of chromogenic reporter activity
in gene-targeted mice. Tissues of wild-type
(WT) and Cyp7b +/ mice stained with a substrate
for LacZ enzyme activity (blue staining). A, liver; panels
are: a, WT, female; b, +/ , male, neonate;
c and d, +/ , male, adult;
e and f, +/ , female, adult.
Scale bars: filled, 100 µm; open, 1 mm. B, kidney; panels are: a, WT, male, adult;
b-d, +/ , male, adult; e, WT, female, adult;
f +/ , female, adult; scale bars are the same as
in A.
|
|
To determine whether reporter activity paralleled expression of the
hybrid gene, in situ hybridization was performed using probes specific for lacZ or for CYP7B. In liver and
kidney, CYP7B expression was robust, but LacZ mRNA was difficult to
detect (Fig. 4, A and
B; for brain expression see the following sections). mRNA patterns (Fig. 4) broadly reflected the distribution of LacZ staining (Fig. 3). CYP7B mRNA was detected in both male and female tissues. In male kidney strong expression was seen in the S3 segment of
the outer stripe of the outer medulla with some expression extending as
medullary rays into cortex, confirmed using a LacZ probe (Fig.
4A). It was not possible from our data to define
unambiguously the cell type within each nephron segment. Nevertheless,
the distribution was only compatible with expression in the S3 segment
of the nephron, with minor extension to the medullary portion of the
collecting duct. The cortical distal convoluted and connecting tubules
were apparently negative for expression. In female CYP7B mRNA
levels were much lower, but again highest in the S3 segment of the
outer stripe with some faint linear low intensity signal in the inner stripe/inner medulla in the collecting ducts (Fig. 4A). In
liver, CYP7B mRNA was dispersed widely through the tissue of both
male and female animals (Fig. 4B) predominantly in the
perivenous zones; overall expression levels were substantially lower in
female than in male. In female kidney and liver the LacZ probe failed
to detect hybrid mRNA.

View larger version (126K):
[in this window]
[in a new window]
|
Fig. 4.
Expression of CYP7B and LacZ mRNA in
gene-targeted mice. In situ hybridization of
kidney (A), liver (B), and brain (C)
used probes as indicated; in A the first two panels are
stained sections; all other panels are in situ hybridization
(contact autoradiography); Ma, male; Fe, female;
+/ , genotype at Cyp7b locus; wt, wild-type.
Subregions CA1, CA3, and dentate gyrus (DG) of the
hippocampal formation are indicated in C.
|
|
Brain Expression; Reporter Activity Is Robustly and Selectively
Expressed in the Dentate Gyrus of Hippocampus with Lesser Expression in
Cerebellum--
Brain sections from heterozygous mice were stained for
reporter enzyme activity. Vivid staining was observed, almost
exclusively restricted to the dentate gyrus of the hippocampal
formation (Fig. 5A). On
prolonged incubation lesser, but significant, reporter activity was
also detected in cerebellum (Fig. 5B). Higher magnification revealed reporter stain close to dentate granule neurons and a subset
of neurons in the dentate hilus; regions CA3 and CA1 of hippocampus
were essentially negative. Dentate gyrus staining was not precisely
colocalized with the cell bodies of the dentate granule neurons;
instead punctate staining was displaced asymmetrically into the
axo-dendritic fields surrounding the dentate neurons (Fig.
5A).

View larger version (79K):
[in this window]
[in a new window]
|
Fig. 5.
Reporter staining in brain of
Cyp7b +/ mice. A, brain and
hippocampal staining: top panel, complete sagittal section
of brain (hematoxylin/eosin staining, red coloration; LacZ
enzyme activity, blue coloration), enlargements below.
B, cerebellar staining. Scales are given as original
magnifications (× 10 or × 40).
|
|
In situ hybridization was used to evaluate the extent to
which reporter enzyme activity mirrors CYP7B gene expression. The patterns of LacZ mRNA and CYP7B mRNA were similar but
not entirely identical, e.g. LacZ mRNA appeared
more strongly in cerebellum than in cortex; the reverse was true using
the CYP7B probe (Fig. 4C). This result may reflect
sequence-specific mRNA turnover. A striking difference emerged
between the staining pattern for LacZ reporter activity and the
distribution of either CYP7B or LacZ mRNA (compare Fig.
5A with Fig. 4C). High levels of CYP7B message
were associated with the dentate gyrus and predominantly with the
neuronal cell layer; this mRNA is probably responsible for the
intense reporter staining seen adjacent to the dentate gyrus. However,
comparable, if marginally lower, levels of CYP7B mRNA were present
in other regions that failed to display any reporter gene activity,
notably in CA3, possibly indicative of post-transcriptional control.
To address the brain distribution of endogenous CYP7B enzyme,
polyclonal antibody was raised in sheep against synthetic CYP7B peptides and used to probe for CYP7B antigen in brain of nontransgenic animals. Preincubation with the primary immunogen confirmed the specificity of the antibody. However, staining was reduced, but not
abolished, by the targeted gene disruption (not shown); the peptide
epitopes selected may be present in other proteins.
Generation of Null Mice; Mice Homozygous for the Insertion Are
Viable but Fail to Accumulate CYP7B mRNA--
To assess the
contribution of CYP7B enzyme to steroid hydroxylation in brain and
other tissues, mice heterozygous for the IRES-lacZ insertion
were intercrossed to produce animals in which CYP7B function is absent.
The distribution of genotypes obtained (46 +/+, 86 +/ , 31 / )
among intercross progeny was not significantly different from a purely
Mendelian ratio. Nevertheless, the sex ratio among the homozygotes
(male, 10; female, 21; from 163 intercross progeny) suggested, but did
not prove, selective loss of males. To confirm disruption of the
Cyp7b gene, Northern analysis was performed; the expected
transcripts at ~2 kb (see Fig. 1) were absent, confirming that the
reporter cassette has inserted into the Cyp7b gene (not
presented). Mice harboring the insertion appeared superficially normal,
at least to 12 months of age, although no detailed studies on
homozygote fertility, liver, kidney, brain, or immune function have yet
been performed in these mice. We conclude that CYP7B enzyme, in mouse,
is not essential for viability.
Cyp7b Gene Disruption Abolishes DHEA 7 -Hydroxylation--
To
evaluate the contribution of CYP7B to steroid/sterol hydroxylation in
different tissues, ex vivo minces from Cyp7b
/ and control mice were incubated with radiolabeled steroids;
reaction products were examined by TLC and autoradiography. Total brain extracts from wild-type mice (including cortex, cerebellum,
hippocampus, and other brain regions) predominantly converted DHEA to
two products (Fig. 6A). The
more abundant polar derivative (21% input material, 15 min reaction
time) comigrated on TLC with recombinant CYP7B enzyme product (Fig.
6A); this we previously showed on the basis of TLC mobility,
gas chromatography with mass spectrometry, and tritium release
experiments to be identical to 7 -hydroxy-DHEA (7HD, Ref. 40). The
second species, termed molecule 1, migrated closely behind the DHEA
substrate and is inferred to be the product of 17 -HSD activity
on DHEA, androstenediol (A/enediol); the extent of brain conversion to
this product was usually low (~3% input material, 15-min
reaction).

View larger version (68K):
[in this window]
[in a new window]
|
Fig. 6.
Ex vivo steroid metabolism (TLC
analysis) in tissues of Cyp7b / mice.
A, brain metabolism of DHEA and A/enediol is abolished by
Cyp7b gene disruption; lanes are: V7b,
recombinant CYP7B enzyme expressed from vaccinia virus; Sp,
spleen; Br, brain; +/+, +/ , or / , genotype
at the Cyp7b locus; S, substrate (no extract);
filled arrowheads, position of substrate application;
open arrowheads, substrate. B, metabolism of
DHEA, A/anediol, and 25-hydroxycholesterol (25-OHChol) is
abolished in both spleen (Sp) and brain (Br).
C, metabolism of DHEA to 7 -hydroxy-DHEA (horizontal
line) is abolished or diminished in several tissues of male and
female mutant mice; paired tracks are extracts from wild-type
(left) and mutant (right) mice; tissues were
brain (Br), spleen (Sp), heart (He),
testis (Te), prostate (Pr), lung (Lu),
thymus (Th), liver (Li), kidney (Ki),
uterus (Ut), mammary gland (Ma). m1,
molecule 1 (see text).
|
|
Brain extracts from heterozygous animals displayed reduced substrate
conversion to 7HD (53% of wild-type level); in homozygous / brain
no conversion of DHEA to 7HD was recorded (Fig. 6A); scanning radiography revealed that 7HD was not detectable over background (less than 0.1% of wild-type conversion level). Reduced 7HD
production was accompanied by a small increase in molecule 1 (~2× in
/ extracts). Conversion of A/enediol (Fig. 6A),
A/anediol, and 25-hydroxycholesterol (Fig. 6B) were also abolished.
Other mouse tissues were examined. Spleen, thymus, heart, lung (male),
prostate, uterus, and mammary gland (Fig. 6C) from Cyp7b / mice failed to convert DHEA to more polar
derivatives, including 7 -hydroxy-DHEA, or were severely impaired in
the conversion (female lung, testis). Liver and kidney metabolism of
DHEA and other steroids is complex; there were nevertheless significant differences in the profiles obtained, particularly in males (Fig. 6C), consistent with the sexual dimorphism of expression.
CYP7B and Steroid 6 -Hydroxylation--
Incubation of extracts
of wild-type mouse brain with radiolabeled A/anediol
(5 -androstane-3 ,17 -diol) yielded one major and two minor
products on TLC; the major product comigrated with the in
vitro conversion product obtained with recombinant CYP7B enzyme (see Fig. 6B; also data not shown) and was
inferred to be 6 -hydroxy-A/anediol; minor products are inferred to
be 7 - and 7 -hydroxylated derivatives. Incubation of total brain
extracts from mutant mice with radiolabeled A/anediol failed to produce more polar derivatives; scanning quantitation of the TLC plate revealed
that the extent of conversion was less than 0.1% of control values,
while extracts from animals heterozygous for the gene disruption showed
intermediate levels of conversion. We conclude that A/anediol is not
hydroxylated in extracts of Cyp7b / mutant brain. The
predominant pathway of A/anediol hydroxylation in brain and other
tissues, including prostate, is reported by several groups to be at the
6 position, rather than at 7 . Because B-ring stereochemistry
differs between 5 -reduced steroids (such as A/anediol) and 5-ene
steroids (including DHEA), we infer, but have not proven here, that
CYP7B catalyzes 6 -hydroxylation of A/anediol. Because this
conversion is abolished by the targeted mutation, we conclude that
CYP7B is responsible for metabolism of A/anediol, and most likely to
6 -hydroxy-A/anediol (5 -androstane-3 ,6 ,17 -triol).
Because tissues of Cyp7b / mice fail to hydroxylate
DHEA, A/anediol, A/enediol, or 25-hydroxycholesterol, and hydroxylation at both the 7 (DHEA, A/enediol, 25-hydroxycholesterol) and
presumably 6 (A/anediol) positions is abolished by the gene
disruption, Cyp7b is likely to encode a major
extrahepatic pathway of steroid/sterol B-ring hydroxylation.
 |
DISCUSSION |
We have used gene targeting to address the relationship of CYP7B
enzyme to the steroid and sterol hydroxylation activities reported in
rodent tissues. Li-Hawkins et al. (47) recently and
independently reported mice in which the Cyp7b gene had been disrupted; their studies centered on cholesterol metabolism in liver.
We now describe transgenic mice in which a reporter gene (lacZ) is inserted into the Cyp7b gene; we report
expression studies and steroid/sterol metabolism in extrahepatic
tissues of the mutant mouse.
Our principal observations are as follows. First, steroid hydroxylation
activity and CY7B mRNA are widely distributed in brain and other
tissues. Second, targeting the mouse Cyp7b gene with an
IRES-lacZ construct generates reporter enzyme activity in
multiple tissues including brain, kidney, and liver; brain reporter
expression was dramatically, if superficially, restricted to
the dentate gyrus. Third, the pattern of reporter activity in brain
failed to match exactly the distribution of CYP7B mRNA or
LacZ mRNA, although the reporter activity/mRNA patterns
in liver and kidney were largely coincident. Fourth, mice lacking CYP7B
activity are viable and superficially normal. Fifth, ex vivo
extracts of homozygous Cyp7b / animals fail to catalyze
hydroxylation of the steroid (and sterol) substrates tested, including
DHEA and 25-hydroxycholesterol. Sixth, the targeted mutation also
abolished hydroxylation (presumed to be at 6 ) of the 5 -reduced
steroid, A/anediol. These aspects are discussed separately below.
CYP7B expression, originally suspected to be most robustly expressed in
hippocampus, is found more widely. Transcripts were readily detected in
rat brain, but also at significant levels in spleen, heart, prostate,
lung, and ovary, in addition to kidney and liver expression in both
mouse and rat (this work and Ref. 36). Relative levels of expression
are difficult to assess precisely, but appeared highest in brain, and
particularly in the dentate gyrus of the hippocampus; high levels are
present in prostate, with significant levels in liver, kidney, heart,
and spleen. The level of mRNA expression in ovary was lower. Three
mRNAs are present in brain and some other tissues: a pair of
transcripts at 2 kb (1.8 and 2.1) and a much larger RNA (~5 kb) that
is prominent in rat but not mouse brain; while the two smaller
transcripts are thought to arise by alternative polyadenylation site
utilization (36), the origin of the larger transcript is not known.
7 -Hydroxylation activity is also widespread, and we report
conversion of DHEA to a molecule comigrating with 7 -hydroxy-DHEA in
several rat and mouse tissues including brain, spleen, thymus, heart,
lung, testis, prostate, uterus, ovary, and mammary gland, although the efficiency of conversion varied between tissues. Liver and kidney metabolism was complex, precluding specific analysis of B-ring hydroxylation. Most of these tissues hydroxylate A/anediol and 25-hydroxycholesterol (this work and data not presented) in addition to
DHEA (this work). In contrast, the potent anesthetic steroid 5 -androstane-3 ,17 -diol was very poorly metabolized by the
majority of these tissues, including brain (not presented). In addition to 7 -hydroxylation of DHEA, we also observed a slightly more slowly
migrating species, molecule 1, that is inferred, on the basis of other
experiments4, to be the
17 -HSD product of DHEA, androstenediol, also a substrate for CYP7B
(40). This emphasizes previous reports that 17 -HSD activity is also
widespread in brain and other tissues (48).
We generated mice harboring a targeted insertion of an
IRES-lacZ reporter cassette. Chromogenic staining was
observed in both liver and kidney, organs in which CYP7B mRNA is
present (Ref. 36 and this work); the staining pattern was similar to
the patterns of CYP7B mRNA or LacZ sequences detected by in
situ hybridization. Staining in kidney was associated with the S3
segment of the outer stripe of the medulla, a region of acid-base and
electrolyte exchange, fuel resorption, and metabolic activity. Liver
staining appeared largely in the perivenous zone of the lobules, where
glycolysis predominates. The function of CYP7B in these regions is not
known. No staining was observed in other tissues analyzed (not
presented), probably because of the insensitivity of this technique,
with the exception of peri-follicular staining in ovary and intense staining in seminiferous tubules.3
In the brain, strikingly vivid reporter staining was seen in the
dentate gyrus of the hippocampus, with only lower levels in cerebellum.
Overt coloration was absent from other brain regions including cortex
and olfactory bulb. Punctate staining in the dentate gyrus is
reminiscent of the pattern seen previously with the kin gene
trap insertion (49) and suggestive of association of the reporter
enzyme with discrete membrane components; these could be a subclass of
synapses or other unidentified structures. Here, in contrast to liver
and kidney, reporter expression failed to parallel either CYP7B or LacZ
mRNA. Staining was restricted to dentate gyrus and, at lower
levels, cerebellum; hippocampal regions CA1-3 were essentially
negative. In contrast, CYP7B mRNA and transgene-encoded LacZ
mRNA were through much of cortex, hippocampus, olfactory bulb, and
cerebellum. Nevertheless, localized LacZ activity reiterates the
restricted expression exploited for CYP7B cDNA isolation (36).
Because DHEA 7-hydroxylation activity is present in microdissected
brain regions including olfactory bulb,
cortex, cerebellum, brainstem, and is
abolished by the mutation,5 our results would seem
to exclude a second unidentified enzyme with significant ex
vivo activity. Possible explanations for the reporter/mRNA
discrepancy include: 1) tissue specificity of IRES elements
(50); 2) structure and/or processing of the hybrid RNA may differ
between dentate and the CA regions; 3) -galactosidase enzyme is
multimeric: LacZ staining may show a threshold effect; 4) possible
post-transcriptional control of CYP7B expression: 7-hydroxylation,
presumably mediated by CYP7B, is modulated by cell density (51, 52),
although the mechanism has not been determined.
Intercrossing heterozygous Cyp7b +/ animals generated
homozygous / animals at or near the expected frequency. Although our data do not rule out some selective perinatal loss of male homozygotes, we conclude that Cyp7b gene function is not
essential for viability in adult mice; a similar conclusion was reached by another group (47). This contrasts with the situation in human,
where CY7B deficiency was associated with abormalities of hepatic
cholesterol metabolism and was incompatible with survival (43). Species
differences in hepatic cholesterol metabolism were previously suggested
by studies on CYP27 (cholesterol 27-hydroxylase): human mutations
produce disordered lipid metabolism, atherosclerosis, and mental
retardation (cerebrotendinous xanthomatosis; Ref. 53); mice lacking
CYP27 display no CTX-related pathological abnormalities (54).
We inspected tissues from Cyp7b / mice for their ability
to catalyze steroid and oxysterol hydroxylation ex vivo.
7 -Hydroxylation of DHEA was abolished in brain, spleen, thymus,
lung, heart, uterus, and mammary gland; gene disruption not only
abolished 7 -hydroxylation of DHEA, but also of pregnenolone,
A/enediol, and 25-hydroxycholesterol. The complexity of steroid and
sterol conversions in transgenic and control liver precluded analysis
of specific B-ring modification. In brain and other tissues, homozygous
disruption of the Cyp7b gene also abolishes the production
of two minor products, probably 7 -hydroxy-DHEA (ascertained by TLC
comigration) and a second product with a TLC migration slightly faster
than 7 -hydroxy-DHEA: this is inferred (but not proven), on the basis
of this and other work (40, 31, 34, 35), to correspond to the
6 -hydroxy derivative of DHEA. Both products are generated in
vitro by recombinant CYP7B enzyme (40). We conclude that minor
modification of DHEA at the 7 and probably 6 positions is an
inherent property of CYP7B enzyme. This contrasts with the conclusion,
on the basis of inhibitor studies, that different enzymes in brain and
prostate are responsible for 7 - and 7 -hydroxylation of DHEA and
pregnenolone (34, 35, 31).
Incubation of A/anediol with extracts of mouse brain (this work) or
recombinant CYP7B enzyme (this work and Ref. 40) yielded, like DHEA,
one major and two minor polar metabolites. The major metabolite of
A/anediol produced by brain ex vivo is
6 -hydroxy-A/anediol (5 -androstane-3 ,6 ,17 -triol) as
reported previously (24-26, 28); this comigrated with the
major CYP7B product. We infer, but have not formally proven, that CYP7B
catalyzes 6 -hydroxylation of A/anediol and that the less abundant
A/anediol metabolites correspond to 7 - and 7 -hydroxylated
derivatives. Ex vivo production of all these molecules was
abolished by Cyp7b gene disruption (<0.1% of the wild-type
conversion level in Cyp7b / extracts).
Disruption of the Cyp7b gene therefore abolishes
hydroxyation of DHEA, pregnenolone, A/enediol, and
25-hydroxycholesterol, at both major (7 ) and minor (7 , 6 ?)
positions. It also abolishes hydroxylation of A/anediol, both at the
major (6 ) position and at minor positions. We suggest that one gene
product, CYP7B enzyme, is responsible for all these activities.
This study does not rule out formally the possibility that different
transcripts from the CYP7B gene might encode physically distinct
enzymes with separate substrate specificities and hydroxylation stereochemistry. We think this unlikely. First, substrate specificity and stereochemistry for these conversions can vary according to reaction conditions (26, 31). Second, the hydroxylation profiles of
DHEA and A/anediol by brain and recombinant CYP7B enzyme are indistinguishable.4
CYP7B is thereby likely to furnish a major extrahepatic and
broad-spectrum steroid/sterol B-ring hydroxylase, with predominant hydroxylation at the 7 position (exemplified by DHEA and oxysterols) complemented by 6 -hydroxylation of some atypical substrates
(exemplified by A/anediol). CYP7B is not the only extrahepatic B-ring
hydroxylase; a testosterone 7 -hydroxylase has been described in
testis (CYP2A9/15: Refs. 55 and 56), while in human (but not rodent)
prostate, 6 -hydroxylation is reported to be performed by a non-P450
enzyme that, unlike CYP7B (this work), modifies steroids with the
5 -3 configuration (32, 57)
What might be the biological role of steroid/sterol B-ring
hydroxylation? In liver, hydroxylation promotes metabolic elimination: oxysterol conversion to bile acids is promoted by CYP7A and CYP7B operating in parallel with a dedicated liver-specific
24(S)-hydroxycholesterol 7 -hydroxylase, CYP39A1 (58).
Hydroxylation may also promote metabolic elimination of testosterone
and progesterone derivatives following 5 -reduction and 3 -HSD
action (see Ref. 28). In other tissues a specific regulatory role for
B-ring modified steroids has been suggested. In addition to feedback
control of cholesterol synthesis by 6- and 7-hydroxylated cholesterols
(59, 60), B-ring-modified sterols may regulate cell death processes and cognitive and immune function (see Ref. 5 for review).
More generally, CYP7B activity may gate steroid access to receptor
targets, either by preventing or potentiating receptor interactions.
The major adrenal steroid DHEA is a case in point: 7-hydroxylation may
generate, or be on the metabolic pathway toward, the bioactive
derivatives that enhance cognitive, immune, and other physiological
processes, notably those that decline (like DHEA levels) with age.
While the specific receptors targeted by 7-modified steroids of this
class remain to be identified, a report that 7-oxo-DHEA is more
effective than DHEA in promoting long term memory retention in old (22 month) mice (61) is suggestive of this interpretation and further
emphasizes that CYP7B-mediated hydroxylation may not be the end of the
metabolic pathway (62). Notably, a mammalian 7 -hydroxysteroid
dehydrogenase activity has been described previously (63).
Receptor gating may also be indirect. Hydroxylation of DHEA and related
steroids may divert these precursors from local sythesis of more active
steroids including corticosteroids and sex steroids. This might be
important in liver and kidney where the striking sexual dimorphism
reflects a similar male preponderance of androgen-sensitive gene
expression. Furthermore, the most potent anesthetic steroids, with the
3 -5 configuration, are not CYP7B substrates, but may compete with
the relatively inert A/anediol for access to cell-surface receptor
channels: hydroxylation of A/anediol could gate this process (28). A
similar process may take place at nuclear receptors: inert 7-oxo
steroids might compete with active hormone (64). Studies on mutant mice
will be required to test these possibilities. Investigations of
cognitive, neuroendocrine, and electrophysiological parameters in the
mutant mice are planned, particularly as a function of age.
 |
ACKNOWLEDGEMENTS |
We thank S. Fleming and R. Brown for expert
advice on kidney histology and M. Warner for helpful discussions and
for providing unpublished data.
 |
FOOTNOTES |
*
This work was supported by grants from the European
Commission (CT-98-0311 (to R. L., J. R. S., and J. A. G.)), the Medical Research Council (to R. L.), the Gatsby
Charitable Foundation (to R. L.), the Wellcome Trust (to J. R. S. and R. L.), and the Swedish Medical Research Council
(to J. A. G.).The costs of publication of this
article were defrayed in part by the
payment of page charges. The article
must therefore be hereby marked
"advertisement" in accordance with 18 U.S.C. Section
1734 solely to indicate this fact.
**
Both authors contributed equally to this paper.

To whom correspondence should be addressed: Centre for Genome
Research, King's Bldgs., West Mains Rd., Edinburgh EH9 3JQ, UK. Tel.:
44-131-650-5890; Fax: 44-131-650-7773; E-mail:
Rlathe@ed.ac.uk.
Published, JBC Papers in Press, April 4, 2001, DOI 10.1074/jbc.M011564200
2
K. Rose, G. Stapleton, and R. Lathe, unpublished data.
3
K. Rose and R. Lathe, unpublished data.
4
E. DeGryse, P. Vico, and R. Lathe, unpublished data.
5
K. Rose, S. Gauldie, and R. Lathe, unpublished data.
 |
ABBREVIATIONS |
The abbreviations used are:
DHEA, dehydroepiandrosterone;
A/anediol, 5 -androstane-3 ,17 -diol (androstanediol);
A/enediol, 5-androstene-3 ,17 -diol (androstenediol);
7HD, 7 -hydroxy-DHEA;
IRES, internal ribosomal
entry signal;
HSD, hydroxysteroid dehydrogenase;
TLC, thin layer
chromatography;
ES cells, embryonic stem cells;
TESPA, 2-aminoproply triethoxyslilane.
 |
REFERENCES |
| 1.
|
Baulieu, E. E.
(1998)
Psychoneuroendocrinology
23,
963-987
|
| 2.
|
Baulieu, E. E.,
and Robel, P.
(1990)
J. Steroid. Biochem. Mol. Biol.
37,
395-403
|
| 3.
|
De Kloet, E. R.,
Vreugdenhil, E.,
Oitzl, M. S.,
and Joels, M.
(1998)
Endocr. Rev.
19,
269-301
|
| 4.
|
McEwen, B. S.,
and Alves, S. E.
(1999)
Endocr. Rev.
20,
279-307
|
| 5.
|
Lathe, R.,
and Seckl, J. R.
(2001)
in
Genetics of Steroid Synthesis and Metabolism
(Mason, J. I., ed)
, Harwood Academic, Amsterdam, in press
|
| 6.
|
Flood, J. F.,
and Roberts, E.
(1988)
Brain Res.
448,
178-181
|
| 7.
|
Flood, J. F.,
Morley, J. E.,
and Roberts, E.
(1992)
Proc. Natl. Acad. Sci. U. S. A.
89,
1567-1571
|
| 8.
|
Flood, J. F.,
Morley, J. E.,
and Roberts, E.
(1995)
Proc. Natl. Acad. Sci. U. S. A.
92,
10806-10810
|
| 9.
|
Daynes, R. A.,
Dudley, D. J.,
and Araneo, B. A.
(1990)
Eur. J. Immunol.
20,
793-802
|
| 10.
|
Danenberg, H. D.,
Ben-Yehuda, A.,
Zakay-Rones, Z.,
and Friedman, G.
(1995)
Vaccine
13,
1445-1448
|
| 11.
|
Padgett, D. A.,
and Loria, R. M.
(1998)
J. Neuroimmunol.
84,
61-68
|
| 12.
|
Orentreich, N.,
Brind, J. L.,
Vogelman, J. H.,
Andres, R.,
and Baldwin, H.
(1992)
J. Clin. Endocrinol. Metab.
75,
1002-1004
|
| 13.
|
Sapolsky, R. M.,
Vogelman, J. H.,
Orentreich, N.,
and Altmann, J.
(1993)
J. Gerontol.
48,
B196-B200
|
| 14.
|
Lane, M. A.,
Ingram, D. K.,
Ball, S. S.,
and Roth, G. S.
(1997)
J. Clin. Endocrinol. Metab.
82,
2093-2096
|
| 15.
|
Morales, A. J.,
Nolan, J. J.,
Nelson, J. C.,
and Yen, S. S.
(1994)
J. Clin. Endocrinol. Metab.
78,
1360-1367
|
| 16.
|
Hinson, J. P.,
and Raven, P. W.
(1999)
J. Endocrinol.
163,
1-5
|
| 17.
|
Wolf, O. T.,
Neumann, O.,
Hellhammer, D. H.,
Geiben, A. C.,
Strasburger, C. J.,
Dressendorfer, R. A.,
Pirke, K. M.,
and Kirschbaum, C.
(1997)
J. Clin. Endocrinol. Metab.
82,
2363-2367
|
| 18.
|
Wolf, O. T.,
Naumann, E.,
Hellhammer, D. H.,
and Kirschbaum, C.
(1998)
J. Gerontol. A Biol. Sci. Med. Sci.
53,
M385-M390
|
| 19.
|
Baulieu, E. E.,
Thomas, G.,
Legrain, S.,
Lahlou, N.,
Roger, M.,
Debuire, B.,
Faucounau, V.,
Girard, L.,
Hervy, M. P.,
Latour, F.,
Leaud, M. C.,
Mokrane, A.,
Pitti-Ferrandi, H.,
Trivalle, C.,
de Lacharriere, O.,
Nouveau, S.,
Rakoto-Arison, B.,
Souberbielle, J. C.,
Raison, J.,
Le Bouc, Y.,
Raynaud, A.,
Girerd, X.,
and Forette, F.
(2000)
Proc. Natl. Acad. Sci. U. S. A.
97,
4279-4284
|
| 20.
|
Li, K.,
Foo, T.,
and Adams, J. B.
(1978)
Steroids
31,
113-127
|
| 21.
|
Isaacs, J. T.,
McDermott, I. R.,
and Coffey, D. S.
(1979)
Steroids
33,
675-692
|
| 22.
|
Guiraud, J. M.,
Samperez, S.,
and Jouan, P.
(1982)
Steroids
40,
625-639
|
| 23.
|
Sundin, M.,
Warner, M.,
Haaparanta, T.,
and Gustafsson, J.-Å.
(1987)
J. Biol. Chem.
262,
12293-12297
|
| 24.
|
Warner, M.,
Strömstedt, M.,
Möller, L.,
and Gustafsson, J.-Å.
(1989)
Endocrinology
124,
2699-2706
|
| 25.
|
Akwa, Y.,
Morfin, R. F.,
Robel, P.,
and Baulieu, E. E.
(1992)
Biochem. J.
288,
959-964
|
| 26.
|
Gemzik, B.,
Green, J.,
and Parkinson, A.
(1992)
Arch. Biochem. Biophys.
296,
355-365
|
| 27.
|
Khalil, M. W.,
Strutt, B.,
Vachon, D.,
and Killinger, D. W.
(1993)
J. Steroid Biochem. Mol. Biol.
46,
585-595
|
| 28.
|
Strömstedt, M.,
Warner, M.,
Banner, C. D.,
MacDonald, P. C.,
and Gustafsson, J.-Å.
(1993)
Mol. Pharmacol.
44,
1077-1083
|
| 29.
|
Zhang, J.,
Larsson, O.,
and Björkhem, I.
(1995)
Biochem. Biophys. Acta
1256,
353-359
|
| 30.
|
Payne, D. W.,
Shackleton, C.,
Toms, H.,
Ben-Shlomo, I.,
Kol, S.,
deMoura, M.,
Strauss, J. F.,
and Adashi, E. Y.
(1995)
J. Biol. Chem.
270,
18888-18896
|
| 31.
|
Doostzadeh, J.,
and Morfin, R.
(1996)
Steroids
61,
613-620
|
| 32.
|
Dombroski, R.,
Casey, M. L.,
and MacDonald, P. C.
(1997)
J. Clin. Endocrinol. Metab.
82,
1338-1344
|
| 33.
|
Doostzadeh, J.,
Cotillon, A. C.,
and Morfin, R.
(1997)
J. Neuroendocrinol.
9,
923-928
|
| 34.
|
Doostzadeh, J.,
Cotillon, A. C.,
and Morfin, R.
(1998)
Steroids
63,
383-392
|
| 35.
|
Doostzadeh, J.,
Cotillon, A. C.,
Benalycherif, A.,
and Morfin, R.
(1998)
Steroids
63,
608-614
|
| 36.
|
Stapleton, G.,
Steel, M.,
Richardson, M.,
Mason, J. O.,
Rose, K. A.,
Morris, R. G.,
and Lathe, R.
(1995)
J. Biol. Chem.
270,
29739-29745
|
| 37.
|
Jelinek, D. F.,
Andersson, S.,
Slaughter, C. A.,
and Russell, D. W.
(1990)
J. Biol. Chem.
265,
8190-8197
|
| 38.
|
Pereira, B.,
Wu, K. K.,
and Wang, L. H.
(1994)
Biochem. Biophys. Res. Commun.
203,
59-66
|
| 39.
|
Eggertsen, G.,
Olin, M.,
Andersson, U.,
Ishida, H.,
Kubota, S.,
Hellman, U.,
Okuda, K. I.,
and Björkhem, I.
(1996)
J. Biol. Chem.
271,
32269-32275
|
| 40.
|
Rose, K. A.,
Stapleton, G.,
Dott, K.,
Kieny, M. P.,
Best, R.,
Schwarz, M.,
Russell, D. W.,
Björkhem, I.,
Seckl, J.,
and Lathe, R.
(1997)
Proc. Natl. Acad. Sci. U. S. A.
94,
4925-4930
|
| 41.
|
Schwarz, M.,
Lund, E. G.,
Lathe, R.,
Björkhem, I.,
and Russell, D. W.
(1997)
J. Biol. Chem.
272,
23995-24001
|
| 42.
|
Church, G. M.,
and Gilbert, W.
(1984)
Proc. Natl. Acad. Sci. U. S. A.
81,
1991-1995
|
| 43.
|
Setchell, K. D.,
Schwarz, M.,
O'Connell, N. C.,
Lund, E. G.,
Davis, D. L.,
Lathe, R.,
Thompson, H. R.,
Weslie Tyson, R.,
Sokol, R. J.,
and Russell, D. W.
(1998)
J. Clin. Invest.
102,
1690-1703
|
| 44.
|
Wu, Z.,
Martin, K. O.,
Javitt, N. B.,
and Chiang, J. Y.
(1999)
J. Lipid Res.
40,
2195-2203
|
| 45.
|
Nehls, M.,
Kyewski, B.,
Messerle, M.,
Waldschutz, R.,
Schuddekopf, K.,
Smith, A. J.,
and Boehm, T.
(1996)
Science
272,
886-889
|
| 46.
|
Mansour, S. L.,
Thomas, K. R.,
and Capecchi, M. R.
(1988)
Nature
336,
348-352
|
| 47.
|
Li-Hawkins, J.,
Lund, E. G.,
Turley, S. D.,
and Russell, D. W.
(2000)
J. Biol. Chem.
275,
16536-16542
|
| 48.
|
Martel, C.,
Rheaume, E.,
Takahashi, M.,
Trudel, C.,
Couet, J.,
Luu-The, V.,
Simard, J.,
and Labrie, F.
(1992)
J. Steroid Biochem. Mol. Biol.
41,
597-603
|
| 49.
|
Steel, M.,
Moss, J.,
Clark, K. A.,
Kearns, I. R.,
Davies, C. H.,
Morris, R. G.,
Skarnes, W. C.,
and Lathe, R.
(1998)
Hippocampus
8,
444-457
|
| 50.
|
Creancier, L.,
Morello, D.,
Mercier, P.,
and Prats, A. C.
(2000)
J. Cell Biol.
150,
275-281
|
| 51.
|
Akwa, Y.,
Sananes, N.,
Gouezou, M.,
Robel, P.,
Baulieu, E. E.,
and Le Goascogne, C.
(1993)
J. Cell Biol.
121,
135-143
|
| 52.
|
Killinger, D. W.,
Strutt, B. J.,
Roncari, D. A.,
and Khalil, M. W.
(1995)
J. Steroid Biochem. Mol. Biol.
52,
195-201
|
| 53.
|
Björkhem, I.
(1994)
Scand. J. Gastroenterol.
204S,
68-72
|
| 54.
|
Rosen, H.,
Reshef, A.,
Maeda, N.,
Lippoldt, A.,
Shpizen, S.,
Triger, L.,
Eggertsen, G.,
Björkhem, I.,
and Leitersdorf, E.
(1998)
J. Biol. Chem.
273,
14805-14812
|
| 55.
|
Sonderfan, A. J.,
Arlotto, M. P.,
and Parkinson, A.
(1989)
Endocrinology
125,
857-866
|
| 56.
|
Kurose, K.,
Isozaki, E.,
Tohkin, M.,
and Fukuhara, M.
(1999)
Arch. Biochem. Biophys.
371,
270-276
|
| 57.
|
Gemzik, B.,
Jacob, S.,
Jennings, S.,
Veltman, J.,
and Parkinson, A.
(1992)
Arch. Biochem. Biophys.
296,
374-383
|
| 58.
|
Li-Hawkins, J.,
Lund, E. G.,
Bronson, A. D.,
and Russell, D. W.
(2000)
J. Biol. Chem.
275,
16543-16549
|
| 59.
|
Axelson, M.,
and Larsson, O.
(1996)
J. Biol. Chem.
271,
12724-12736
|
| 60.
|
Song, C.,
Hiipakka, R. A.,
and Liao, S.
(2000)
Steroids
65,
423-427
|
| 61.
|
Shi, J.,
Schulze, S.,
and Lardy, H. A.
(2000)
Steroids
65,
124-129
|
| 62.
|
Lardy, H.,
Partridge, B.,
Kneer, N.,
and Wei, Y.
(1995)
Proc. Natl. Acad. Sci. U. S. A.
92,
6617-6619
|
| 63.
|
Song, W.,
Chen, J.,
Dean, W. L.,
Redinger, R. N.,
and Prough, R. A.
(1998)
J. Biol. Chem.
273,
16223-16228
|
| 64.
|
Chang, H. C.,
Miyamoto, H.,
Marwah, P.,
Lardy, H.,
Yeh, S.,
Huang, K. E.,
and Chang, C.
(1999)
Proc. Natl. Acad. Sci. U. S. A.
96,
11173-11177
|
| 65.
|
Stapleton, G.
(1994)
Gene Expression in the Hippocampus: Identification of a Novel Cytochrome P450.Ph.D. thesis
, University of Edinburgh
|
Copyright © 2001 by The American Society for Biochemistry and Molecular Biology, Inc.

CiteULike Complore Connotea Del.icio.us Digg Reddit Technorati What's this?
This article has been cited by other articles:

|
 |

|
 |
 
K. Karu, M. Hornshaw, G. Woffendin, K. Bodin, M. Hamberg, G. Alvelius, J. Sjovall, J. Turton, Y. Wang, and W. J. Griffiths
Liquid chromatography-mass spectrometry utilizing multi-stage fragmentation for the identification of oxysterols
J. Lipid Res.,
April 1, 2007;
48(4):
976 - 987.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
T. Nishiyama, T. Nakamura, K. Obara, H. Inoue, K. Mishima, N. Matsumoto, M. Matsui, T. Manabe, K. Mikoshiba, and I. Saito
Up-Regulated PAR-2-Mediated Salivary Secretion in Mice Deficient in Muscarinic Acetylcholine Receptor Subtypes
J. Pharmacol. Exp. Ther.,
February 1, 2007;
320(2):
516 - 524.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. L. W. Yau, J. Noble, M. Graham, and J. R. Seckl
Central Administration of a Cytochrome P450-7B Product 7{alpha}-Hydroxypregnenolone Improves Spatial Memory Retention in Cognitively Impaired Aged Rats
J. Neurosci.,
October 25, 2006;
26(43):
11034 - 11040.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C Suarez, J Vela, I Garcia-Tornadu, and D Becu-Villalobos
Dehydroepiandrosterone (DHEA) modulates GHRH, somatostatin and angiotensin II action at the pituitary level
J. Endocrinol.,
April 1, 2005;
185(1):
165 - 172.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
Y. Omoto, R. Lathe, M. Warner, and J.-A. Gustafsson
Early onset of puberty and early ovarian failure in CYP7B1 knockout mice
PNAS,
February 22, 2005;
102(8):
2814 - 2819.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
Y. Omoto, O. Imamov, M. Warner, and J.-A. Gustafsson
Estrogen receptor {alpha} and imprinting of the neonatal mouse ventral prostate by estrogen
PNAS,
February 1, 2005;
102(5):
1484 - 1489.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C. Martin, M. Ross, K. E. Chapman, R. Andrew, P. Bollina, J. R. Seckl, and F. K. Habib
CYP7B Generates a Selective Estrogen Receptor {beta} Agonist in Human Prostate
J. Clin. Endocrinol. Metab.,
June 1, 2004;
89(6):
2928 - 2935.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
Z. Weihua, R. Lathe, M. Warner, and J.-A. Gustafsson
An endocrine pathway in the prostate, ERbeta , AR, 5alpha -androstane-3beta ,17beta -diol, and CYP7B1, regulates prostate growth
PNAS,
October 15, 2002;
99(21):
13589 - 13594.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
G. J. Pass, W. Becker, R. Kluge, K. Linnartz, L. Plum, K. Giesen, and H.-G. Joost
Effect of Hyperinsulinemia and Type 2 Diabetes-Like Hyperglycemia on Expression of Hepatic Cytochrome P450 and Glutathione S-Transferase Isoforms in a New Zealand Obese-Derived Mouse Backcross Population
J. Pharmacol. Exp. Ther.,
August 1, 2002;
302(2):
442 - 450.
[Abstract]
[Full Text]
[PDF]
|
 |
|
Copyright © 2001 by the American Society for Biochemistry and Molecular Biology.
|
Advertisement
Advertisement
|